Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin US Launches On Track But Albuterol 'Clarity' Awaited

Defers FDA Reinspection Timelines

Executive Summary

After lower growth in India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.

You may also be interested in...



Cipla To Recalibrate US Investments, Partnering Plan For Specialty Business

Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”

Lupin Adds To US Portfolio

The launch of injectable doxercalciferol and FDA approvals for mycophenolic acid delayed-release tablets and betamethasone dipropionate ointment could add some cheer to Lupin whose high-potential launches in the US have seen delays. However, analysts are not very enthused.

Lupin-Aptar Launch India’s First Smart Device For MDIs At $22 Apiece

As the Indian pharma industry catches up with digitization, Lupin partners with Aptar to launch a smart device for MDIs. While there is a need for the product, whether it will find favor in a price-sensitive market remains to be seen. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141637

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel